There is a fast-growing need for anti-microbial paints and coatings to improve quality in residential, commercial, institutional, and industrial applications to control the growth of mold and/or reduce the risk of healthcareassociated infections or community-acquired infections. A number of paint products available in the market claims anti-microbial functions. However, the current products have significant shortfalls, including weak activities, risk of resistance from virus, and difficulty in monitoring & extending the anti-microbial functions once the coatings are applied.

Alcohol enzymes encompass all enzyme products that are used in various stages of alcohol production. They are added into the production process to enhance, improve, or catalyze the alcohol fermentation process to obtain high product yield and low production costs. They are a part of industrial enzymes that are developed and produced for use in distilled alcohol production, beer brewing, wine making, and for biofuel production. Currently, most of the enzymes are produced from genetically modified (GM) microorganisms. The global alcohol enzymes market analyzes various enzymes offered by key players in the market. The market is segmented into type and end users.

近日，国家医疗保障局发布了《医疗机构医疗保障定点管理暂行办法》和《零售药店医疗保障定点管理暂行办法》，自2021 年2 月1 日起施行。

2020年疫苗合计批签发6.51亿，同比增长14.39%。其中一类苗批签发3.48亿，同比增长0.62%，二类苗批签发3.03亿，同比增长35.76%，是自12年以来，二类苗最高增速。国产疫苗6亿，同比增长13.68%，国产疫苗已扫去两次疫苗事件阴霾，进口疫苗批签发总量近8年最高达到0.51亿，同比增长23.46%。疫苗行业在新冠疫情影响下，疾控进一步推动终端疫苗的宣传和接种，进而提高疫苗的渗透率，批签发量增速显著，疫苗行业迎来新机遇。

2020年疫苗合计批签发6.51亿，同比增长14.39%。其中一类苗批签发3.48亿，同比增长0.62%，二类苗批签发3.03亿，同比增长35.76%，是自12年以来，二类苗最高增速。国产疫苗6亿，同比增长13.68%，国产疫苗已扫去两次疫苗事件阴霾，进口疫苗批签发总量近8年最高达到0.51亿，同比增长23.46%。疫苗行业在新冠疫情影响下，疾控进一步推动终端疫苗的宣传和接种，进而提高疫苗的渗透率，批签发量增速显著，疫苗行业迎来新机遇。

2020Q4 延续逐季恢复态势，全年业绩加速趋势明显：我们对重点覆盖的57 家医药上市公司2020 全年业绩进行了预测，预计2020 全年净利润增速超过50%的有10 家；净利润增速30%-50%的有11 家；净利润增速20%-30%的有17 家；净利润增速0-20%的有11 家；净利润同比下滑的公司有7 家；进行经营情况预测更新但暂不预测利润端的公司共1 家。

投资建议：重点推荐康泰生物、智飞生物、华兰生物、长春高新，关注康希诺生物、万泰生物、康华生物。国内疫苗产品的换代升级是趋势，重点关注新型创新疫苗与多价多联疫苗的上市进度。

2020年国内血制品批签发总量达9827.37万，同比增长16.68%，其中白蛋白5891.24万（+19.04%）、免疫球蛋白类3434.08万（+9.32%）、凝血因子类502.05万（+51.19%）。白蛋白依旧占据国内血制品行业主导地位，凝血因子类增速最高。

11 月，中检院合计批签发血制品846.37 万瓶，同比下降11.91%；1-11 月，中检院累计批签发血制品9131.17 万瓶，同比增长12.83%。